Novo Nordisk A/S
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NONOF | NVS | LLY | AZN | PFE | BMY | |
|---|---|---|---|---|---|---|
| Market cap | 172.73B | 286.29B | 1.12T | 256.54B | 168.60B | 122.05B |
| P/E (TTM) | 9.6 | 22.8 | 42.2 | 23.8 | 38.9 | 13.2 |
| Forward P/E | — | 15.4 | 26.6 | 14.6 | 10.2 | 9.0 |
| Price/book | 5.2 | 6.9 | 33.1 | 5.1 | 2.0 | 5.5 |
| Dividend yield | 4.56% | 3.15% | 0.55% | 1.94% | 5.81% | 4.22% |
| 1-year change | −28.34% | +14.29% | +55.39% | −1.39% | +19.81% | +37.07% |
| Today | −0.66% | +0.16% | +0.43% | −0.76% | +0.48% | −1.35% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All NONOF news ›Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know
Novo Nordisk A/S (NVO) moved up by 3.38%. The Pharmaceuticals & Medical Research sector is up by 2.38%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Eli Lilly and Co (LLY) up 4.62%; Moderna Inc (MRNA) up…
Novo Nordisk A/S - share repurchase programme
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement 5 October, the following transactions have…
Reviewing Tarsus Pharmaceuticals (NASDAQ:TARS) and Novo Nordisk A/S (NYSE:NVO)
Posted by Michael Walen on Oct 10th, 2026 Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Novo Nordisk A/S (NYSE:NVO – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
Novo Nordisk A/S : Insider Transactions
Follow insider transactions on Novo Nordisk A/S in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Novo Nordisk A/S Latest insider transactions for Novo Nordisk A/S All…
Novo Nordisk A/S : JP Morgan is Neutral
Published on 10/05/2026 at 07:45 am EDT Novo Nordisk and Eli Lilly trade blows September 29, 2026 at 09:34 am EDT Novo Nordisk: Aiming below the mark Novo Sues Rival Lilly Over Weight-Loss Ads
Novo Nordisk A/S: Latest Headlines - Nasdaq Copenhagen Stock Exchange
Novo Nordisk and Eli Lilly trade blows September 29, 2026 at 09:34 am EDT Novo Nordisk: Aiming below the mark Novo Sues Rival Lilly Over Weight-Loss Ads GLP-1: The Winners and Losers of Shifting Consumer Habits
Novo Nordisk A/S: Relative Strength Chart - Stock Nasdaq Copenhagen
Compare Novo Nordisk A/S with the company of your choice via a Relative Strength chart. Real-time NOVO B price, Nasdaq Copenhagen stock exchange Relative Strength Chart Novo Nordisk A/S All financial news and data tailored to specific…
Novo Nordisk A/S : Deutsche Bank gives a Sell rating
Published on 10/07/2026 at 03:28 am EDT Novo Nordisk and Eli Lilly trade blows September 29, 2026 at 09:34 am EDT Novo Nordisk: Aiming below the mark Novo Sues Rival Lilly Over Weight-Loss Ads
Novo Nordisk A/S: Total Return chart (Dividends reinvested) - Nasdaq Copenhagen stock market
See the history of Novo Nordisk A/S, with dividends reinvested. (Total Return chart) NOVO B Stock market Total Return chart Novo Nordisk A/S Past dividends on Novo Nordisk A/S All financial news and data tailored to specific country…
Novo Nordisk A/S: Official Announcements - Stock Market News
Novo Nordisk and Eli Lilly trade blows September 29, 2026 at 09:34 am EDT Novo Nordisk: Aiming below the mark Novo Sues Rival Lilly Over Weight-Loss Ads GLP-1: The Winners and Losers of Shifting Consumer Habits
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com13
-
manilatimes.net2
-
stocktitan.net2
-
defenseworld.net1
-
fool.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 24 articles, not a forecast.